KLTO (Klotho Neurosciences) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Days Payable?

Klotho Neurosciences's average Accounts Payable for the three months ended in Dec. 2024 was $0.17 Mil. Klotho Neurosciences's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Klotho Neurosciences's Days Payable or its related term are showing as below:

KLTO's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 122.89
* Ranked among companies with meaningful Days Payable only.

Klotho Neurosciences's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Klotho Neurosciences Days Payable Historical Data

The historical data trend for Klotho Neurosciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Days Payable Chart

Klotho Neurosciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Days Payable

Klotho Neurosciences Quarterly Data
	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Klotho Neurosciences's Days Payable

For the Biotechnology subindustry, Klotho Neurosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Klotho Neurosciences's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Days Payable falls into.

Save Embed

;

Save Embed

;

Klotho Neurosciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Klotho Neurosciences's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (0.151	+	0.064)	/	2 )	/	0	*	365
=	0.1075					/	0	*	365
=	N/A

Klotho Neurosciences's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (0.271	+	0.064)	/	2 )	/	0	*	365 / 4
=	0.1675					/	0	*	365 / 4
=	N/A

Klotho Neurosciences Days Payable Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Klotho Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

13576 Walnut Street, 12th Floor, Omaha, NE, USA, 68144

Website

https://www.klothoneuro.com

Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.